Key Vascular Endothelial Growth Factor Inhibitors Market PLayers:
- Regeneron Pharmaceuticals
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Bayer AG
- Novartis AG
- Roche (Genentech)
- Amgen Inc.
- Biogen
- Coherus BioSciences
- Bausch Health Companies
- Viatris Inc.
- Eli Lilly and Company
- Bristol Myers Squibb
- Exelixis, Inc.
- Takeda Pharmaceuticals
- Eisai Co., Ltd.
- Sanofi (Regeneron)
The competition in the market is high, with Regeneron, Bayer, and Novartis at its forefront. There is also a drive for expanding product indications, development of biosimilars, and improvements in delivery systems to ease patient comfort. Regeneron, for instance, has offered higher doses of Eylea for more convenient dose intervals. Furthermore, collaborations are the new trend. As an example, Bristol Myers Squibb and BioNTech are allied to co-develop a PD-L1/VEGF-A bispecific antibody, BNT327, for cancer treatment. These strategic moves are pointing to innovations aiming to cater to the unmet medical needs within the VEGF inhibitors industry.
Here is a list of key players operating in the global market:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of vascular endothelial growth factor inhibitors is evaluated at USD 16.1 billion.
Vascular endothelial growth factor (VEGF) inhibitors market size was valued at USD 15.2 billion in 2025 and is set to exceed USD 26.1 billion by 2035, registering over 6.2% CAGR during the forecast period i.e., between 2026-2035.
North America industry is expected to hold largest revenue share by 2035, as a result of rising investments by government and private entities in research and development of cancer therapies and treatments, including VEGF inhibitor drugs.
The major players in the market are Pfizer, Inc., Novartis AG, GlaxoSmithKline plc, Sanofi, AstraZeneca plc, Bristol-Myers-Squibb Company, Genentech, Inc. (Roche), Merck & Co., Inc., Bayer AG and Eli Lilly & Company.
